Aclarion (NASDAQ:ACON), a commercial-stage healthcare technology company, has closed a $10.4 million common-stock-only financing, significantly bolstering its balance sheet as it seeks to transform the diagnosis of chronic low back pain.
AbbVie (NYSE:ABBV) has entered into a voluntary three-year agreement with the Trump administration, pledging a massive $100 billion investment in U.S.-based research, development, and manufacturing over the next decade.
Visionary Holdings (NASDAQ:GV) shares are under pressure after the company’s 2025 annual report revealed a significant revenue contraction and mounting liquidity concerns.
Argenx SE (NASDAQ:ARGX) shares are in focus after the U.S. Food and Drug Administration accepted a supplemental Biologics License Application for Vyvgart with Priority Review, potentially expanding the drug's reach to a difficult-to-treat subset of patients with generalized myasthenia gravis (gMG).
Biodesix (NASDAQ:BDSX) shares surged in early Monday trading after the lung diagnostics firm reported preliminary 2025 revenue that eclipsed its own upwardly revised guidance.
The company’s focus on high-margin lung cancer testing and a strategic expansion into primary care drove a 41% revenue spike in the fourth quarter.
Karyopharm Therapeutics (NASDAQ:KPTI) is entering a pivotal year for its oncology pipeline, with the company forecasting a duo of high-stakes clinical trial readouts that could redefine its market position as its current cash runway nears its end.
Boston Scientific Corp. (NYSE:BSX) has entered into a definitive agreement to acquire Valencia Technologies Corp., a private medical technology firm, in a strategic move to dominate the high-growth market for overactive bladder treatments.
BioAge Labs (NASDAQ:BIOA) shares climbed Monday after the longevity-focused biotech reported that its experimental oral drug, BGE-102, sharply reduced systemic inflammation in a mid-stage study of obese patients.
Nuvation Bio (NYSE:NUVB) reported preliminary 2025 revenue that beat internal projections, driven by the rapid adoption of its flagship lung cancer treatment, IBTROZI®.
Planet Fitness (NYSE:PLNT) reported a surge in year-end membership and same-club sales for 2025, signaling that its low-cost "Judgment Free Zone" model is continuing to capture market share among younger, budget-conscious consumers.
Lipocine (NASDAQ:LPCN) experimental oral treatment for postpartum depression passed its final independent safety review, clearing the path for a critical data readout later this spring.
Hyperfine (NASDAQ:HYPR), the medical technology firm behind the first portable, AI-powered brain imaging system, reported a dramatic surge in fourth-quarter revenue, signaling a potential turning point for its bedside MRI technology.
